|
|
 |
July 29, 2008 |
Now Available:
Watch video podcasts of the 2008 EULAR press conferences
CME Opportunity:
Musculoskeletal Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts.
MSK Report distributes biweekly and special edition newsletters, making it the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.
With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.
| MSK Poll | |
|
Help us expand our coverage: What topic are you most interested in reading about? |
|
Autoimmunity: New High-Resolution Device Aids Finger MRI in Scleroderma
High-resolution magnetic resonance angiography (micro-MRA) can readily measure vascular disease of fingers in systemic sclerosis...
Arthritis: NHS TNF Inhibitor Restrictions Heighten Impact of Baseline DAS28 in RA
The British National Institute for Health and Clinical Excellence (NICE) guidelines for approving access to TNF inhibitors for patients with rheumatoid arthritis (RA) may be unnecessarily extending the period when steroids are not allowed and classifying >30% of patients as "nonresponders" who would not be allowed to continue anti-TNF treatment...
Consumer News: Complaints Undermine Hip Device
Sales of the Durom cup, an artificial hip socket, have been suspended following complaints by doctors of a high failure rate...
BioPharm Business: CEL-SCI Announces Positive Preclinical Results Using CEL-2000, a Chimeric Peptide with Bi-Functional Properties, as RA Vaccine
CEL-SCI Corp announced the discovery of CEL-2000, a novel peptide vaccine for the treatment of RA. Tests showed that CEL-2000 is equivalent or possibly superior to Enbrel in slowing disease progression and lessening symptoms in mice...
BioPharm Business: Chelsea Therapeutics Granted UK MHRA Approval to Begin Phase II Trial of Droxidopa, a Prodrug of Norepinephrine, in Fibromyalgia
Droxidopa, an orally active synthetic amino acid precursor of norepinephrine (NE), is converted by the body into norepinephrine and as a prodrug of NE, provides replacement therapy for NE deficiency...